Table 1.
Baseline characteristics of all participants.
| Baseline characteristics | Control (n = 42) | Randomised to active intervention (n = 89) | Declined active intervention (n = 38) | Accepted active intervention (n = 51) | Completed active intervention (n = 41) |
|---|---|---|---|---|---|
| Age, median (range) | 63 (40–80) | 64 (35–86) | 64 (36–86) | 63 (35–86) | 64 (41–86) |
| Female sex, n (%) | 18 (43%) | 41 (46%) | 17 (45%) | 24 (47%) | 18 (49%) |
| Ethnicity, n (%) | |||||
| White | 36 (86%) | 74 (83%) | 35 (92%) | 29 (77%) | 32 (78%) |
| Black | 3 (7%) | 9 (10%) | 1 (3%) | 8 (16%) | 5 (12%) |
| Asian | 3 (7%) | 4 (5%) | 1 (3%) | 3 (6%) | 3 (7%) |
| Other | 0 (0%) | 2 (2%) | 1 (3%) | 1 (2%) | 1 (2%) |
| Type of myeloma | |||||
| IgG | 27 (64%) | 52 (58%) | 22 (58%) | 30 (59%) | 24 (59%) |
| IgA | 5 (12%) | 15 (17%) | 7 (18%) | 8 (16%) | 7 (17%) |
| Light chain | 7 (17%) | 17 (19%) | 8 (21%) | 9 (18%) | 7 (17%) |
| Non-secretory/oligo-secretory | 3 (7%) | 5 (6%) | 1 (3%) | 4 (8%) | 3 (7%) |
| Autologous stem-cell transplantation | |||||
| No | 4 (10%) | 14 (16%) | 7 (18%) | 7 (14%) | 6 (15%) |
| Yes | 38 (90%) | 75 (84%) | 31 (82%) | 44 (86%) | 35 (86%) |
| On maintenance treatment | 4 (10%) | 18 (20%) | 8 (21%) | 10 (20%) | 10 (24%) |
| Bone disease | 29 (69%) | 61 (69%) | 24 (63%) | 37 (73%) | 29 (71%) |
| Pain | 13 (31%) | 35 (39%) | 15 (39%) | 20 (39%) | 16 (39%) |
| Prior surgery | 11 (26%) | 16 (18%) | 7 (18%) | 9 (18%) | 8 (20%) |
| Radiotherapy | 8 (19%) | 23 (26%) | 9 (24%) | 14 (28%) | 9 (22%) |
| Time since treatment, median (range), months | 20 (2, 251) | 14 (2, 161) | 15 (2, 161) | 13 (2, 138) | 12 (2, 84) |
| ECOG performance score | |||||
| 0 | 33 (79%) | 70 (79%) | 31 (82%) | 39 (76%) | 31 (76%) |
| 1 | 9 (21%) | 19 (21%) | 7 (18%) | 12 (24%) | 10 (24%) |